Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Alliance for Clinical Trials in Oncology
Sponsor:
Collaborators:
National Cancer Institute (NCI)
Celgene Corporation
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT02004275
First received: November 26, 2013
Last updated: November 16, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)